Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.40 |
| ▸ | LIPE | Q05469 | 6/20 | 0.40 |
| ▸ | SYK | P43405 | 4/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14814689 | 0.78 | MEN1 (0.44) | MEN1KMT2ASMYD3LIPESYK | |
| SCHEMBL14815461 | 0.77 | LIPE (0.41) | LIPECNR1 | |
| SCHEMBL14815376 | 0.76 | LIPE (0.38) | MEN1KMT2ALIPESYKCNR1 | |
| SCHEMBL14814700 | 0.76 | KDM4E (0.44) | SYKCYP2D6CYP2C19NPSR1 | |
| SCHEMBL14815261 | 0.74 | LIPE (0.34) | SMYD3LIPE | |
| SCHEMBL14814935 | 0.74 | NTRK1 (0.34) | LIPESYKCNR1 | |
| SCHEMBL14815136 | 0.74 | LIPE (0.42) | LIPE | |
| SCHEMBL14815371 | 0.73 | RBP4 (0.44) | SYK | |
| SCHEMBL14815225 | 0.73 | RBP4 (0.44) | SYK | |
| SCHEMBL14815419 | 0.73 | CCR2 (0.37) | LIPE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130085142-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS | ABBVIE INC. (US) | 2013-04-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085142-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS | CACNA1C, CACNA1E, CACNA1D | MEN1 1008/4885KMT2A 2999/4885SMYD3 1460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.